A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca AB
Start Date
November 16, 2020
End Date
April 7, 2023
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca AB
Start Date
November 16, 2020
End Date
April 7, 2023